The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | AVO achieves high rates of undetectable MRD in CLL
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase II study (NCT03580928) investigating a combination of acalabrutinib, venetoclax and obinutuzumab (AVO) as a frontline therapy for chronic lymphocytic leukemia (CLL). The study found that 78% of CLL patients receiving AVO therapy achieved bone marrow undetectable measurable residual disease (MRD) after 15 months of time-limited therapy. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Matthew Davids, MD, has participated in scientific advisory boards, has done consultancy work or has received honoraria from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, Celgene, Eli Lilly, Genentech, Janssen, MEI Pharma, Merck, Novartis, Pharmacyclics, TG Therapeutics, Verastem and Research to Practice; and has received research funding from Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem.
